Cargando…

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance. However, the contributions of histone methylatransferase SET and MYND domain containing 3 (SMYD3) to sorafenib resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shanshan, You, Xin, Liu, Xiaoshu, Fengwei Zhang, Zhou, Hongjuan, Shang, Xuechai, Cai, Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391607/ https://www.ncbi.nlm.nih.gov/pubmed/37534166 http://dx.doi.org/10.1016/j.isci.2023.106994

Ejemplares similares

Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
por: Wang, Shanshan, et al.
Publicado: (2020)

SMYD3 promotes the epithelial–mesenchymal transition in breast cancer
por: Fenizia, Claudio, et al.
Publicado: (2019)

Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma
por: Binh, Mai Thanh, et al.
Publicado: (2020)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
por: Fouquet, Grégory, et al.
Publicado: (2022)

The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways
por: Adenina, Syarinta, et al.
Publicado: (2020)

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Dong, Shuying, et al.
Publicado: (2015)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis
por: Kim, Kwangho, et al.
Publicado: (2023)

Role of Smad3 signaling in the epithelial-mesenchymal transition of the lens epithelium following injury
por: Meng, Fanlan, et al.
Publicado: (2018)

DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD
por: Li, Yang-ling, et al.
Publicado: (2022)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

[Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑β/Smad2/3 signaling pathway
por: Kou, Bo, et al.
Publicado: (2023)

Sinomenine Relieves Airway Remodeling By Inhibiting Epithelial-Mesenchymal Transition Through Downregulating TGF-β1 and Smad3 Expression In Vitro and In Vivo
por: He, Hongjuan, et al.
Publicado: (2021)

Repression of Smad3 by silencing Robo1 attenuates epithelial-mesenchymal transition in tracheobronchial stenosis
por: He, Chunyan, et al.
Publicado: (2023)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

circSMAD2 inhibits the epithelial–mesenchymal transition by targeting miR-629 in hepatocellular carcinoma
por: Zhang, Xianwei, et al.
Publicado: (2018)

ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma
por: Zhou, Zhenyu, et al.
Publicado: (2019)

The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways
por: Liang, Shufang, et al.
Publicado: (2018)

TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3
por: Chen, Zhanjun, et al.
Publicado: (2022)

Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation
por: Park, Sujin, et al.
Publicado: (2018)

Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation
por: Park, Sujin, et al.
Publicado: (2018)

Lyn regulates epithelial–mesenchymal transition in CS-exposed model through Smad2/3 signaling
por: Liang, Xiaobo, et al.
Publicado: (2019)

Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
por: Dong, Jiejie, et al.
Publicado: (2017)

14-3-3ε Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma
por: Liu, Tzu-An, et al.
Publicado: (2013)

Regulation of epithelial-mesenchymal transition by protein lysine acetylation
por: Kong, Fanyun, et al.
Publicado: (2022)

Corrigendum to “The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways”
por: Liang, Shufang, et al.
Publicado: (2022)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters
por: Zhang, Heyun, et al.
Publicado: (2021)

Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor
por: Modi, Siddharth J., et al.
Publicado: (2021)

KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification
por: Kuang, Ye, et al.
Publicado: (2022)

DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC
por: Liu, Yan-Ping, et al.
Publicado: (2016)

MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3
por: Liu, Ping, et al.
Publicado: (2016)

Baicalin and puerarin reverse epithelial-mesenchymal transition via the TGF-β1/Smad3 pathway in vitro
por: Wu, Tao, et al.
Publicado: (2018)

Thalidomide Inhibits TGF-β1-induced Epithelial to Mesenchymal Transition in Alveolar Epithelial Cells via Smad-Dependent and Smad-Independent Signaling Pathways
por: Zhou, Xian-Long, et al.
Publicado: (2017)

Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
por: Zhang, Juyong, et al.
Publicado: (2013)

Baicalin inhibits the TGF-β1/p-Smad3 pathway to suppress epithelial-mesenchymal transition-induced metastasis in breast cancer
por: Liu, Ding-Kuo, et al.
Publicado: (2020)

Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by Krüppel-like factor 4
por: Li, Qi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ikgqf7jhnqn8ndaou71373r12e